FDA OKs 1st generic nasal spray of overdose reversal drug
Top News

FDA OKs 1st generic nasal spray of overdose reversal drug

  • ASSOCIATED PRESS / 2018

    In this photo, Narcan nasal spray is shown outside a pharmacy in Greenfield, Mass. U.S. regulators have approved the first generic nasal spray version of Narcan, a drug that reverses opioid overdoses.

U.S. regulators have approved the first generic nasal spray version of Narcan, a drug that reverses opioid overdoses.

The Food and Drug Administration today OK’d naloxone spray from Israel’s Teva Pharmaceuticals.

Naloxone has been sold as a nasal spray in the U.S. since 2016 under the brand name Narcan. Pharmacists can dispense it without a prescription. It is also sold as a generic or brand-name drug in automatic injectors, prefilled syringes and vials.

A pack of two Narcan nasal sprays cost about $130 to $150 without insurance. Teva didn’t immediately provide the product’s price or when it will be available; its offices were closed today.

More than 47,600 Americans died of opioid overdoses in 2017, a toll that has been rising for two decades.

Comments (0)

By participating in online discussions you acknowledge that you have agreed to the Terms of Service. An insightful discussion of ideas and viewpoints is encouraged, but comments must be civil and in good taste, with no personal attacks. If your comments are inappropriate, you may be banned from posting. Report comments if you believe they do not follow our guidelines.

Having trouble with comments? Learn more here.

Scroll Up